Navigation Links
Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
Date:4/7/2013

WAYNE, N.J., April 8, 2013 /PRNewswire/ -- Bayer HealthCare announced today that the New Drug Application (NDA) for its oral investigational compound riociguat has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or with persistent or recurrent CTEPH after pulmonary endarterectomy (PEA) and pulmonary arterial hypertension (PAH).

Both CTEPH and PAH are life-threatening diseases.  CTEPH is a form of pulmonary hypertension in which blood clots and thromboembolic occlusion of pulmonary vessels leads to increased pressure in the pulmonary arteries.  PAH is a disease characterized by elevated pressure in the pulmonary arteries.

"We are pleased that the FDA has granted priority review of the riociguat NDA for two distinct forms of pulmonary hypertension," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "This milestone reinforces our commitment to advancing treatment options for cardio-pulmonary diseases, and brings us one step closer to potentially providing the first pharmacological treatment for inoperable or persistent/recurrent CTEPH and a new treatment option for PAH."

The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA aims to complete its review within six months of the 60-day filing receipt of the NDA submission (eight months total), rather than the standard 12-month review cycle.

The NDA submission is supported by data from two global Phase III studies of riociguat CHEST-1 and PATENT-1. Data from these two studies were presented in October 2012 at CHEST, the annual meeting of the American College of Chest Physicians (ACCP). Both Phase III studies on ri
'/>"/>

SOURCE Bayer HealthCare
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
2. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
4. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
5. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
6. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
7. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
11. Healthpoint Biotherapeutics Initiates Phase III Study of Unique Investigational Cell-Based Therapy for Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today confirmed the PDUFA date for Zalviso remains July ... a rumor circulated online stating the Food and Drug ... 2014 there has been no notification to the company ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of ... including next-generation sequencing (NGS) gene panels, for blood cancers  ... by new test, indicate favorable prognosis for patients with ... QIAGEN sees potential for developing companion diagnostics to guide ...
(Date:7/24/2014)... 24, 2014 Amgen (NASDAQ: AMGN ) ... results on Tuesday, July 29, 2014, after the close of ... a conference call with the investment community at 2 p.m. ... Robert A. Bradway , chairman and chief executive officer, and ... audio of the conference call will be simultaneously broadcast over ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... CAESAREA, Israel, March 23, 2011 EndyMed ... use of multi-source radiofrequency for professional aesthetic treatments, announced ... on 3DEEP radiofrequency technology, "A novel method ... treatments". This article was published ...
... CLEVELAND, March 23, 2011 DATATRAK International, Inc. ... on global eClinical solutions for the clinical trials ... Information Association,s EuroMeeting. The 23rd Annual EuroMeeting will ... while evaluating the benefits new science and technologies ...
Cached Medicine Technology:EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 2EndyMed Medical's Novel Multi-Source Radiofrequency Device Enables Real Time Skin Impedance Measurements 3DATATRAK to Attend DIA's 23rd Annual EuroMeeting 2
(Date:7/25/2014)... Mateo, CA (PRWEB) July 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... and show times TBA. , For more than four ... the Bay Area community through its residential alcohol and ... will educate on Project Ninety's humble idea and how ...
(Date:7/25/2014)... July 25, 2014 Home Care Assistance ... provider of non-medical, in-home senior care, is weighing in ... be supporting senior-led projects in Alberta through their New ... for Seniors Program is a federal grants and contributions ... who make a difference in the lives of others ...
(Date:7/25/2014)... 25, 2014 The Futon Shop ... Futon Sale. The Futon Shop has been around since 1976 ... has grown from a few handmade futon mattresses a month, ... of futon mattresses. , The Futon Shop futon mattresses ... the desire to sleep on natural fibers was a growing ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry ... products and services for infectious disease diagnostic development, ... RP Multimarker Controls - MDZ001 . , ... CE marked, unassayed external run control intended for ... RP Multimarker Controls - MDZ001 has been specifically ...
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
Breaking Medicine News(10 mins):Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 2Health News:Organic Mattress Manufacturer Celebrates 38 Years Of Being In Business 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3
... in Central Pennsylvania Earn Designation, CAMP HILL, ... to announce the recognition of Penn State Hershey ... Centers for Complex and Rare,Cancers., Complex and ... cases each year, making it difficult for patients ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that ... present at,two upcoming investor conferences, one sponsored by Cowen ... Bell will present at the Cowen and Company 27th ... on Tuesday, March 18, 2008.,Dr. Bell will also present ...
... Celebration and ... NEW YORK, March 11 Autism Speaks, the world,s ... to mark the inaugural celebration of World Autism Awareness ... disorder,affecting millions of individuals and families around the world. ...
... Children,s Hospitals to Deliver Specialized Pediatric Patient Education at ... ... BETHESDA, Md. and WILMINGTON, Del., March 11 ,GetWellNetwork, Inc., ... the largest provider of online pediatric health,information, today announced a ...
... fight against increasing obesity, according to internationally regarded expert ... , Its becoming well known that there are high ... has significant consequences for chronic diseases, both physical and ... known is that not only blood vessels to the ...
... Appointment broadens reach of expanding care and care ... the,Brentwood, Tenn.-based provider of care management for the ... care policy expert,Stuart Altman has been appointed to ... expert care and care management company focused on,improving ...
Cached Medicine News:Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Health News:Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 2Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 3Health News:Autism Speaks to Celebrate World Autism Awareness Day with Day-Long Series of International Events on April 2 4Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 2Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 3Health News:GetWellNetwork and KidsHealth Partner to Empower Pediatric Patients and Their Families 4Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 2Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: